Soligenix Inc. (NASDAQ: SNGX) announced that it has received a positive opinion from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) for its pipeline product dusquetide in the treatment of Behçet's disease. This opinion represents a critical regulatory milestone for the company, validating the scientific rationale behind dusquetide and potentially accelerating its development path.
The positive opinion paves the way for the European Commission to grant orphan drug designation, which would provide incentives including protocol assistance, reduced regulatory fees, and up to 10 years of market exclusivity following approval. For patients living with rare inflammatory diseases like Behçet's disease, such regulatory milestones can mean the difference between stalled research and meaningful therapeutic progress.
Dusquetide is classified as an innate defense regulator, a type of compound designed to modulate the body's innate immune system rather than suppress it outright. This mechanism of action is particularly relevant for Behçet's disease, a chronic inflammatory condition characterized by recurrent oral and genital ulcers, skin lesions, and ocular inflammation, for which there is currently no cure. The disease represents an area of unmet medical need, with limited treatment options available.
Soligeniz CEO and president Christopher J. Schaber, PhD expressed enthusiasm about the development, stating, 'We are extremely pleased to have received the positive opinion from the COMP and look forward to the European Commission granting the orphan drug designation for the SGX945 program.' The company is focused on developing treatments for rare diseases and areas of unmet medical need, and this milestone underscores its commitment to advancing dusquetide.
The announcement follows the company's broader efforts to advance its pipeline. For more information about Soligenix and its programs, visit the company's newsroom at https://ibn.fm/SNGX.
This development is part of the coverage provided by BioMedWire, a specialized communications platform focusing on the latest developments in the biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is one of over 75 brands within the Dynamic Brand Portfolio @IBN that delivers access to a vast network of wire solutions, article and editorial syndication to over 5,000 outlets, enhanced press release distribution, social media distribution, and tailored corporate communications solutions. For more information, visit https://www.BioMedWire.com.
The positive opinion from the COMP is a significant step forward for Soligenix as it continues to develop dusquetide for Behçet's disease, potentially offering new hope to patients suffering from this rare and debilitating condition.
